ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1172

Can Uric Acid Blood Levels in Renal Transplant Recipients Predict Allograft Outcome?

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Isakov, Ofer, Souraski Medical Center, Tel Aviv, Israel
  • Schwartz, Doron, Souraski Medical Center, Tel Aviv, Israel
  • Hod, Tamar, Souraski Medical Center, Tel Aviv, Israel
Background

Hyperuricemia is common after renal transplantation, especially in those receiving calcineurin inhibitors (CNI). Increased uric acid (UA) levels were found predictive of kidney disease and end-stage renal disease in those with normal renal function and disease progression in individuals with kidney disease. Little, however, is known about the relationship between UA levels and allograft outcome.

Methods

We conducted a retrospective single-center analysis (N=368) in order to assess UA blood levels posttransplant association with allograft outcome.

Results

Patients were divided into 2 groups based on the mean UA level measured between 1-12 months posttransplant. Those with mean UA level ≥ 7 and 6.5 mg/dL (N = 164) versus mean UA level< 7 and 6.5 mg/dL for men and women respectively (N=204) had lower GFR values at 1, 3 and 5 years posttransplant. In a multivariate analysis adjusted for age, gender, race, transplant type, mean CNI levels, presence of slow graft function (SGF) and baseline allograft function (GFR at 3 months posttransplant) the association of UA levels to allograft function were not significantly associated with differences in GFR at 1, 3 and 5 years posttransplant.

Conclusion

Hyperuricemia is a surrogate for a worse allograft function. After adjustment for baseline allograft function increased UA levels were not found to be an independent predictor of long-term allograft function despite the known association of hyperuricemia with progression of cardiovascular and renal disease.

Baseline Characteristics of the High versus low UA groups
 High UA (N=164)Low UA (N=204)P Value
Age (years)52.24 (13.76)51.38 (13.92)0.553
Males 84 (51.2) 124 (60.8) 0.083
Whites99 (60.4) 134 (65.7) 0.462
Blacks40 (24.4) 38 (18.6)  
LD70(42.7)138(67.6)<0.001
DCD-ECD57(34.8)35(17.2) 
SCD37(22.6)31(15.2) 
SGF 86 (52.4) 61 (29.9) <0.001
GFR 3M (ml/min) 43.33 (15.06)58.37 (17.84)<0.001
GFR 1Y (ml/min) 45.92 (17.30) 60.77 (19.70)<0.001
GFR 3Y (ml/min)43.42 (20.64) 58.02 (19.87)<0.001
GFR 5Y (ml/min)41.81 (21.38)53.59 (23.12)0.009

Continuous variables are presented as means (and standard deviations), categorical variables are presented as number of patients (and % of the entire group).